[most Hong Kong biomedical stocks rose more than 23%]. As of press time, Cornstone Pharmaceutical-B (02616.HK) rose 23.02%, Clover Bio-B (02197.HK) rose 15.60%, Corning Jerry Pharmaceutical-B (09966.HK) rose 10.92%, Hua Medicine-B (02142.HK) rose 10.20%. Among them, Cornerstone Pharmaceutical led the gain. the company announced that Nature Cancer, a subsidiary of the internationally renowned journal Nature, published online the results of the overall survival time (OS) analysis of GEMSTONE-302, a registered clinical study of sulgarizumab in the first-line treatment of stage IV non-small cell lung cancer (NSCLC).